Related Experiment Video

Updated: Jul 26, 2026

Robotic Ablation of Atrial Fibrillation
11:21

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

Propafenone for the treatment of severe ventricular arrhythmias

S W Rabkin, C E Rotem, K Boroomand-Rashti

    Canadian Medical Association Journal
    |September 15, 1984
    PubMed

    Insights

    Propafenone effectively treated severe ventricular arrhythmias in patients unresponsive to other drugs. This new antiarrhythmic agent demonstrated significant efficacy with a low incidence of adverse effects.

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Severe ventricular arrhythmias pose a significant clinical challenge.
    • Existing antiarrhythmic agents may be ineffective or poorly tolerated in some patients.

    Purpose of the Study:

    • To evaluate the efficacy and safety of propafenone.
    • To assess propafenone's utility in patients with refractory ventricular arrhythmias.

    Main Methods:

    • A study involving 21 patients with severe ventricular arrhythmias.
    • Treatment with the novel antiarrhythmic agent, propafenone.

    Main Results:

    • Complete or near-complete suppression of premature ventricular beats was observed in 71% of patients.
    • Satisfactory control was achieved in 19%, with no control in 10%.
    • Most patients experienced no adverse effects; common complaints included nausea and dizziness.

    Conclusions:

    • Propafenone is an effective antiarrhythmic medication for difficult-to-treat ventricular arrhythmias.
    • The agent exhibits an acceptable side effect profile in this patient population.

    More Related Videos

    Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation08:56

    Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation

    Published on: September 24, 2021

    Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats05:12

    Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats

    Published on: February 14, 2022

    Related Concept Videos

    Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

    Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

    Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
    Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
    Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

    Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

    Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
    Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

    Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

    Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
    Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

    Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

    Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
    Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
    Dysrhythmias VI: Management of Dysrhythmias01:25

    Dysrhythmias VI: Management of Dysrhythmias

    Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
    ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

    ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

    Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...